Alembic Pharmaceuticals Ltd
NSE:APLLTD

Watchlist Manager
Alembic Pharmaceuticals Ltd Logo
Alembic Pharmaceuticals Ltd
NSE:APLLTD
Watchlist
Price: 917.4 INR -1.49%
Market Cap: 180.3B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one APLLTD stock under the Base Case scenario is 1 236.66 INR. Compared to the current market price of 917.4 INR, Alembic Pharmaceuticals Ltd is Undervalued by 26%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

APLLTD Relative Value
Base Case
1 236.66 INR
Undervaluation 26%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.8
P/S
P/S
Price to Sales
2.8
vs History
55
vs Industry
40
Median 3Y
2.6
Median 5Y
2.9
Industry
2.4
Forward
2.8
More Details
29.8
P/E
P/E
Price to Earnings
29.8
vs History
36
vs Industry
15
Median 3Y
31.8
Median 5Y
27.8
Industry
20.5
Forward
31.8
More Details
44.1
P/OCF
P/OCF
Price to OCF
44.1
vs History
7
vs Industry
9
Median 3Y
24.5
Median 5Y
21.1
Industry
15.4
More Details
83.2
P/FCFE
P/FCFE
Price to FCFE
83.2
vs History
39
vs Industry
6
Median 3Y
80.5
Median 5Y
70.7
Industry
22.6
More Details
3.7
P/B
P/B
Price to Book Value
3.7
vs History
46
vs Industry
19
Median 3Y
3.1
Median 5Y
3.5
Industry
2
More Details
3
EV/S
EV/S
Enterprise Value to Sales
3
vs History
49
vs Industry
38
Median 3Y
2.7
Median 5Y
2.9
Industry
2.5
Forward
2.9
More Details
4
EV/GP
EV/GP
Enterprise Value to Gross Profit
4
vs History
52
vs Industry
48
Median 3Y
3.7
Median 5Y
4
Industry
4.9
More Details
19.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
19.3
vs History
26
vs Industry
19
Median 3Y
18.5
Median 5Y
16
Industry
12.6
Forward
18.9
More Details
26.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
26.8
vs History
36
vs Industry
17
Median 3Y
28
Median 5Y
24.6
Industry
15.6
Forward
25.9
More Details
46.9
EV/OCF
EV/OCF
Enterprise Value to OCF
46.9
vs History
7
vs Industry
9
Median 3Y
24.9
Median 5Y
21
Industry
13.9
More Details
236.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
236.8
vs History
7
vs Industry
2
Median 3Y
75.7
Median 5Y
42
Industry
17.7
More Details
3.1
EV/IC
EV/IC
Enterprise Value to IC
3.1
vs History
42
vs Industry
24
Median 3Y
2.7
Median 5Y
2.8
Industry
1.8
More Details

Multiples Across Competitors

APLLTD Competitors Multiples
Alembic Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Alembic Pharmaceuticals Ltd
NSE:APLLTD
183B INR 2.8 29.8 19.3 26.8
US
Eli Lilly and Co
NYSE:LLY
778.6B USD 17.3 73.5 42.7 47.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
392.6B USD 4.4 27.9 13.1 17.1
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7.3 21.1 13.9 15.8
CH
Roche Holding AG
SIX:ROG
234.7B CHF 4 20.4 11.4 13.5
CH
Novartis AG
SIX:NOVN
199B CHF 4.4 18.9 11.4 14.6
UK
AstraZeneca PLC
LSE:AZN
173.6B GBP 4.2 32 126.7 193.5
US
Merck & Co Inc
NYSE:MRK
221.8B USD 3.5 13 8.8 10.4
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
141.7B USD 2.2 17.6 8.5 12.1
P/E Multiple
Earnings Growth PEG
IN
Alembic Pharmaceuticals Ltd
NSE:APLLTD
Average P/E: 28.3
29.8
16%
1.9
US
Eli Lilly and Co
NYSE:LLY
73.5
48%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.9
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
21.1
19%
1.1
CH
Roche Holding AG
SIX:ROG
20.4
16%
1.3
CH
Novartis AG
SIX:NOVN
18.9
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
32
36%
0.9
US
Merck & Co Inc
NYSE:MRK
13
17%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.6
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Alembic Pharmaceuticals Ltd
NSE:APLLTD
Average EV/EBITDA: 397.2
19.3
18%
1.1
US
Eli Lilly and Co
NYSE:LLY
42.7
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.1
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.4
8%
1.4
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126.7
9%
14.1
US
Merck & Co Inc
NYSE:MRK
8.8
9%
1
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.5
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Alembic Pharmaceuticals Ltd
NSE:APLLTD
Average EV/EBIT: 1 702.2
26.8
22%
1.2
US
Eli Lilly and Co
NYSE:LLY
47.2
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.1
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
15.8
16%
1
CH
Roche Holding AG
SIX:ROG
13.5
9%
1.5
CH
Novartis AG
SIX:NOVN
14.6
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
193.5
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.4
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.1
10%
1.2

See Also

Summary
APLLTD intrinsic value, competitors valuation, and company profile.
DCF Valuation
APLLTD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
APLLTD stock valuation using valuation multiples.
Wall Street Estimates
APLLTD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
APLLTD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 241,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.